Cannabis Science Published on HIV Haven.com ?Cannabinoid Research Shows Promise for HIV TAT Inhibition? Authored by Dr. Robert Melamede, Ph.D. and Dr. David Miller, Ph.D.

COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--Jun 13, 2012 - Cannabis Science (CBIS), a pioneering U.S. Biotech Company developing pharmaceutical products for global public health challenges is pleased to announce the Company has published an article on HIV Haven (www.hivhaven.com), a dynamic international HIV community website. The article entitled “Cannabinoid Research Shows Promise for HIV TAT Inhibition” is written by Dr. Robert Melamede, Ph.D., President of Cannabis Science Inc., and Dr. David Miller, Ph.D., an AIDS treatment activist.

The article focuses on recent research, which demonstrated the ability of Phytocannabinoids to inhibit HIV TAT a vital function of HIV, as well as Cannabis Sciences' recently launched Cannabinoid inhibitory HIV TAT platform called CS-TATI-1.

Dr. Robert Melamede, Ph.D., President & CEO of Cannabis Science stated, “We are very happy to present this article on HIV Haven that demonstrates the promise of cannabinoid research in HIV. Community support in influencing important drug development is exemplified no where better than amongst AIDS treatment activists and the global HIV community. We expect to create further interest at the 19th International AIDS Conference (AIDS 2012) this July at our presentation which will take place at the World AIDS Institute AIDS 2012 Reunion Treatment Horizon Satellite symposium series.”

“HIV Haven, like other HIV media outlets, is very aware of the crisis in HIV drug resistance currently facing people with HIV worldwide. This article will hopefully stimulate further interest in this promising arena leading to the further investigation of the relationship between phytocannabinoids and TAT. Cannabis Science is currently the only company looking at the commercial development of a Phytocannabinoid based TAT inhibitor and we hope to understand more about the promise of CS-TATI-1 as it matures through preclinical development,” stated Jeannie Wraight, Editor-in-Chief of HIV Haven.

About CS-TATI-1

Data published in March by researchers at the Mount Sinai School of Medicine found that cannabinoids inhibit TAT induced migration to TAT via cannabinoid 2 receptors (CB2). Funding for the Mount Sinai study was provided by a National Institutes of Health (NIH) Clinical and Translational Science Award Grant. Cannabis Science's research of CS-TATI-1 will be targeted to newly diagnosed patients infected with drug resistant virus, treatment experienced patients with drug-resistant HIV strains, and those intolerant of currently available therapies. Cannabis Science will be pursuing a wide range of NIH based Federal Research Programs such as RO1's, PO1's and SBIRS which exist to support preclinical development of target validation and proof of concept studies. These studies will be implemented through collaborations with leading scientific institutions. Cannabis Science will also be pursuing other clinical research collaborations including the AIDS Clinical Trials Groups (ACTG), the Canadian AIDS Trial Network (CATN) and the European AIDS Trial Network (EATN).

About HIV

HIV's ability to mutate and reproduce itself even in the presence of antiretroviral drugs, has led to a growing rate of drug resistance. Increasing drug resistance is severely limiting treatment options for HIV patients around the world, increasing direct and indirect health costs, furthering the spread of drug resistant strains of HIV and is creating a pressing need to develop new HIV drugs.

The U.S. government invests billions of dollars a year in HIV/AIDS research, treatment and care through a variety of programs. The Ryan White CARE Act, which funds the treatment and care of people living with HIV in the U.S., totals $2.3 billion a year. Among its many other contributions to fighting HIV/AIDS globally, the U.S. provides $22.8 million annually to The U.S. Military HIV Research Program and approximately $1 billion per year to The Global Fund to Fight AIDS, Tuberculosis and Malaria. Pharmaceutical sales to treat HIV equal US $10.6 billion annually. Treatment cost per patient in the U.S. for HIV antivirals alone is approximately US $15,000 a year.

About HIV Haven (www.hivhaven.com)

HIV Haven is an international website that caters to people infected and affected by HIV and those working in the HIV field. HIV Haven provides its readers with daily HIV news in the U.S. and across the globe, articles on various HIV topics, blogs written by a multitude of people including Timothy Brown, the only man cured of HIV. HIV haven is an official sponsor of AIDS2012 Reunion (www.aids2012reunion.com) and the official host of AIDS2012 Reunion news.

About Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of cannabinoid research and development for unmet medical needs. The Company works with leading experts such as Dr. Roscoe M. Moore Jr., DVM, MPH, Ph.D., U.S. Assistant Surgeon General (Retired) for HIV drug development, medicinal characterization, and clinical research to develop, produce, and commercialize Phytocannabinoid-based pharmaceutical products.

As well, Cannabis Science is currently working with CBR International to develop a Pre-IND Application to the FDA that focuses on the use of CS-S/BCC-1 topical cannabis-based preparations for the treatment of basal and squamous cell carcinomas.

Forward Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

 

Contact: Cannabis Science Inc.
Dr. Robert J. Melamede, Ph.D.
President & CEO
1-888-889-0888
info@cannabisscience.com
www.cannabisscience.com
or
Robert Kane
VP Investor Relations
1-561-234-6929
rkane@cannabisscience.com
info@cannabisscience.com
www.cannabisscience.com

 

Posted: June 2012

View comments

Hide
(web3)